依达拉奉（Radicava）：一种用于治疗肌萎缩侧索硬化症的新型神经保护剂。
Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis.
作者信息
Cruz Martin Paspe
出版信息
P T. 2018 Jan;43(1):25-28.
Abstract
Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis.
摘要
依达拉奉（瑞得生）：一种用于治疗肌萎缩侧索硬化症的新型神经保护剂。
相似文献
1
2
Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch.依达拉奉（edaravone）治疗肌萎缩侧索硬化症：上市后 1 年的美国经验。
Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):605-610. doi: 10.1080/21678421.2019.1645858. Epub 2019 Jul 31.
3
Edaravone: a new hope for deadly amyotrophic lateral sclerosis.依达拉奉：治疗致命性肌萎缩侧索硬化症的新希望。
Drugs Today (Barc). 2018 Jun;54(6):349-360. doi: 10.1358/dot.2018.54.6.2828189.
4
In brief: Edaravone oral suspension (Radicava ORS) for ALS.简而言之：用于肌萎缩侧索硬化症的依达拉奉口服混悬液（Radicava ORS）。
Med Lett Drugs Ther. 2022 Sep 5;64(1658):e1.
5
Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.依达拉奉治疗肌萎缩侧索硬化症的疗效和安全性：系统评价和荟萃分析。
Neurol Sci. 2019 Feb;40(2):235-241. doi: 10.1007/s10072-018-3653-2. Epub 2018 Nov 27.
6
Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis.利鲁唑-三唑杂合物作为肌萎缩侧索硬化症神经保护的新型化学探针。
ACS Med Chem Lett. 2018 May 30;9(6):552-556. doi: 10.1021/acsmedchemlett.8b00103. eCollection 2018 Jun 14.
7
Edaravone (Radicava) for ALS.依达拉奉（瑞必乐）用于治疗肌萎缩侧索硬化症。
Med Lett Drugs Ther. 2017 Nov 6;59(1533):180-182.
8
Edaravone for the treatment of amyotrophic lateral sclerosis.依达拉奉治疗肌萎缩侧索硬化。
Expert Rev Neurother. 2019 Mar;19(3):185-193. doi: 10.1080/14737175.2019.1581610. Epub 2019 Feb 27.
9
Edaravone for amyotrophic lateral sclerosis: More evidence for long-term benefit.依达拉奉治疗肌萎缩侧索硬化症：长期获益的更多证据。
Muscle Nerve. 2020 Feb;61(2):129-130. doi: 10.1002/mus.26770. Epub 2019 Dec 13.
10
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.力如太与依达拉奉：两种肌萎缩侧索硬化症药物的故事。
Med Res Rev. 2019 Mar;39(2):733-748. doi: 10.1002/med.21528. Epub 2018 Aug 12.
引用本文的文献
1
Perspectives in Amyotrophic Lateral Sclerosis: Biomarkers, Omics, and Gene Therapy Informing Disease and Treatment.肌萎缩侧索硬化症的展望：生物标志物、组学及为疾病与治疗提供信息的基因疗法
Int J Mol Sci. 2025 Jun 13;26(12):5671. doi: 10.3390/ijms26125671.
2
Amyotrophic Lateral Sclerosis: Pathophysiological Mechanisms and Treatment Strategies (Part 2).肌萎缩侧索硬化症：病理生理机制与治疗策略（第二部分）
Int J Mol Sci. 2025 May 29;26(11):5240. doi: 10.3390/ijms26115240.
3
Alzheimer's Disease and Frontotemporal Dementia: A Review of Pathophysiology and Therapeutic Approaches.阿尔茨海默病与额颞叶痴呆：病理生理学与治疗方法综述
J Neurosci Res. 2025 May;103(5):e70046. doi: 10.1002/jnr.70046.
4
Nanoscale domains govern local diffusion and aging within FUS condensates.纳米级区域控制FUS凝聚物中的局部扩散和老化。
Res Sq. 2025 Apr 14:rs.3.rs-6406576. doi: 10.21203/rs.3.rs-6406576/v1.
5
Drug repurposing in amyotrophic lateral sclerosis (ALS).肌萎缩侧索硬化症（ALS）中的药物重新利用。
Expert Opin Drug Discov. 2025 Apr;20(4):447-464. doi: 10.1080/17460441.2025.2474661. Epub 2025 Mar 7.
6
Mitigation of cholestasis-associated hepatic and renal injury by edaravone treatment: Evaluation of its effects on oxidative stress and mitochondrial function.依达拉奉治疗减轻胆汁淤积相关的肝和肾损伤：评估其对氧化应激和线粒体功能的影响。
Liver Res. 2020 Nov 10;5(3):181-193. doi: 10.1016/j.livres.2020.10.003. eCollection 2021 Sep.
7
The Effects of Antioxidant Approved Drugs and Under Investigation Compounds with Potential of Improving Sleep Disorders and their Associated Comorbidities Associated with Oxidative Stress and Inflammation.经批准的抗氧化药物以及正在研究的具有改善睡眠障碍及其与氧化应激和炎症相关的合并症潜力的化合物的作用。
Mini Rev Med Chem. 2025;25(10):795-815. doi: 10.2174/0113895575360959250117073046.
8
Oxidative/Nitrosative Stress, Apoptosis, and Redox Signaling: Key Players in Neurodegenerative Diseases.氧化/亚硝化应激、细胞凋亡与氧化还原信号传导：神经退行性疾病的关键因素
J Biochem Mol Toxicol. 2025 Jan;39(1):e70133. doi: 10.1002/jbt.70133.
9
Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for amyotrophic lateral sclerosis.骨髓间充质干细胞衍生的细胞外囊泡输注治疗肌萎缩侧索硬化症。
Neurodegener Dis Manag. 2024;14(3-4):111-117. doi: 10.1080/17582024.2024.2344396. Epub 2024 May 28.
10
Understanding Amyotrophic Lateral Sclerosis: Pathophysiology, Diagnosis, and Therapeutic Advances.了解肌萎缩侧索硬化症：病理生理学、诊断和治疗进展。
Int J Mol Sci. 2024 Sep 15;25(18):9966. doi: 10.3390/ijms25189966.
本文引用的文献
1
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.依达拉奉（MCI-186）治疗肌萎缩侧索硬化症患者疗效与安全性的验证性双盲、平行组、安慰剂对照研究。
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610-7. doi: 10.3109/21678421.2014.959024. Epub 2014 Oct 6.
2
Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation?运动症状的肌萎缩侧索硬化症区域性扩散能否用朊病毒样传播来解释？
J Neurol Neurosurg Psychiatry. 2012 Jul;83(7):739-45. doi: 10.1136/jnnp-2011-301826. Epub 2012 Apr 27.
3
Clinical diagnosis and management of amyotrophic lateral sclerosis.肌萎缩侧索硬化症的临床诊断与管理。
Nat Rev Neurol. 2011 Oct 11;7(11):639-49. doi: 10.1038/nrneurol.2011.153.
4
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.C9ORF72 上的六核苷酸重复扩展是 9p21 连锁 ALS-FTD 的原因。
Neuron. 2011 Oct 20;72(2):257-68. doi: 10.1016/j.neuron.2011.09.010. Epub 2011 Sep 21.
5
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.非编码区 C9ORF72 内的 GGGGCC 六核苷酸重复扩展导致 9 号染色体连锁额颞叶痴呆和肌萎缩侧索硬化症。
Neuron. 2011 Oct 20;72(2):245-56. doi: 10.1016/j.neuron.2011.09.011. Epub 2011 Sep 21.
6
An estimate of amyotrophic lateral sclerosis heritability using twin data.利用双胞胎数据估计肌萎缩侧索硬化症的遗传性。
J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1324-6. doi: 10.1136/jnnp.2010.207464. Epub 2010 Sep 22.
7
Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数更新：肌萎缩侧索硬化症患者的护理：多学科护理、症状管理及认知/行为障碍（循证综述）：美国神经病学学会质量标准小组委员会报告
Neurology. 2009 Oct 13;73(15):1227-33. doi: 10.1212/WNL.0b013e3181bc01a4.
8
Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数更新：肌萎缩侧索硬化症患者的护理：药物、营养和呼吸治疗（循证综述）：美国神经病学学会质量标准小组委员会报告
Neurology. 2009 Oct 13;73(15):1218-26. doi: 10.1212/WNL.0b013e3181bc0141.
9
Living with amyotrophic lateral sclerosis/motor neurone disease (ALS/MND): decision-making about 'ongoing change and adaptation'.与肌萎缩性侧索硬化症/运动神经元病（ALS/MND）共存：关于“持续变化和适应”的决策。
J Clin Nurs. 2009 Mar;18(5):745-54. doi: 10.1111/j.1365-2702.2008.02671.x.
10
Amyotrophic lateral sclerosis: A 40-year personal perspective.肌萎缩侧索硬化症：40年的个人视角。
J Clin Neurosci. 2009 Apr;16(4):505-12. doi: 10.1016/j.jocn.2008.07.072. Epub 2009 Feb 23.
Zotero 插件